The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under the brand name Brinsupri. File Photo by John Angelillo/UPI For the first ...

A chronic cough can be due to many things from asthma to post-COVID-19. Here's how to figure out why you can't stop coughing ...

In bronchiectasis, highly symptomatic patients have a greater risk of exacerbations and may benefit from long-term macrolide treatment.

Queen's University Belfast-led research reports on a multicenter trial finding no significant reduction in pulmonary ...

The lung disease bronchiectasis plays out as a vicious cycle. Infection leads to inflammation followed by the impaired ability to clear the excess mucus coughed up from the lungs. These problems lead ...

Brinsupri is an oral inhibitor of dipeptidyl peptidase 1 and targets neutrophilic serine proteases, which mediate ...

Mucoactive agents did little to stave off pulmonary exacerbations of non-cystic fibrosis bronchiectasis, the CLEAR trial showed. In the two-by-two factorial trial testing hypertonic saline and ...